Biotechnology company Enveric Biosciences Inc (NASDAQ:ENVB) announced on Wednesday that it has received a second Notice of Allowance from the United States Patent and Trademark Office for novel compounds in its EVM401 Series, strengthening its intellectual property portfolio in neuropsychiatric drug development.

The approved patent covers a class of methylone-inspired, non-hallucinogenic mescaline derivatives designed as modulators of neurotransmitters linked to psychiatric conditions, including post-traumatic stress disorder.

These benzodioxole analogs are structurally distinct from methylone, an MDMA analog recently linked to positive Phase 2 data in PTSD, and offer patentable differentiation, unlike methylone, which lacks composition of matter protection.

Enveric's proprietary compounds are engineered to deliver therapeutic benefit without hallucinogenic effects, potentially easing regulatory hurdles and enabling broader clinical application.

The company anticipates further preclinical testing to assess safety, pharmacokinetics, and activity against PTSD and related psychiatric disorders.

This second patent allowance supports the expansion of Enveric's pipeline and aligns with its strategy to develop next-generation neuroplastogenic therapeutics.